New therapies for the treatment of type 2 diabetes: an update
DOI:
https://doi.org/10.1002/edn.141Keywords:
Type 2 diabetes, GLP-1 analogues, gliptins, DPP-4 inhibitors, SGLT-2 inhibitorsAbstract
AbstractIn type 2 diabetes, several lesions have been identified and drugs are being developed that target these lesions. This review considers agents that have been introduced to Europe since 2006, particularly the glucagon-like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 inhibitors (gliptins) that represent new classes of agent, both of which target the enteroinsular axis. The GLP-1 analogues and gliptins reduce hyperglycaemia without promoting weight gain, with the former being associated with weight loss. Agents advanced in development, new fixed-dose combination tablets and new formulations of established agents are also considered.
Downloads
References
Day C, Bailey CJ. A diabetologist's herbal. Curr Med Lit Diabetes 1988; 5: 31–35.
Krentz AJ, Bailey CJ. Oral antidiabetic agents. Current role in type 2 diabetes mellitus. Drugs 2005; 65: 385–411.
Day C. New therapies available for the treatment of type 2 diabetes. Eur Diabetes Nursing 2006; 3: 65–70.
Krentz AJ, Patel MB, Bailey CJ, . New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008; 68: 2131–2162
Day C. Amylin analogue as an antidiabetic agent. Br J Diabetes Vasc Dis 2005; 5: 151–154.
Irwin N, Moodley M, Flatt PR, Maximising the therapeutic potential of glucagon-like peptide-1 analogues in the treatment of type 2 diabetes. Br JDiabetes Vasc Dis 2009; 9: 44–52.
Buse JIB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes:a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39–47.
Campell IW, Day C. Sitagliptin - enhancing incretin action. Br J Diabetes Vasc Dis 2007; 7: 134–139.
Bailey CJ, Day C. Fixed dose single-tablet antidiabetic combinations. Diabetes Obes Metabol 2009; 11: 527–533.
Galvus 50mg tablets. Summary of Product Characteristics. December 2008 (http://emc.medicines.org.uk; accessed 18 August 2009).
Cruxtall JD, Keam SJ. Vildagliptin: a review of its use in the management of type 2 diabetes mellitus. Drugs 2008; 68: 2387–2409.
DeFronzo RA, Hissa MN, Garber AJ, et al. The efficacy and safety of saxagliptin when added to met-formin therapy in patients with inadequately controlled type 2 diabetes on metformin alone. Diabetes Care 2009; May 28 (Epub ahead of print].
Deacon CF, Holst jJ. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Ado Ther 2009; 26: 488–499.
VeroScience website for Cycloset (http://www.cycloset.com/Vero; accessed 18 August 2009).
Jabbour SA, Goldstein BJ. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008; 62: 1279–1284.
Wilding JP, Norwood P, T'joen C, et al A study of dapagliflozin in patients with type 2 diabetes on high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009 June 15 [Epub ahead of print].
List JF, Woo V, Morales E, et al. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009; 32: 650–657.
Bailey CJ, Barnett AH. Why is Exubera being withdrawn? Br Med J 2007; 335: 1156.
Christensen R, Kristensen PK, Bartels EM, et al Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 2007; 370: 1706–1713.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2009 Copyright © 2009 FEND
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
